Incomplete endothelialization of intracoronary stents has been associated with stent thrombosis and recurrent symptoms, whereas prolonged use of dual antiplatelet therapy increases bleeding-related adverse events. Facilitated endothelialization has the potential to improve clinical outcomes in patients who are unable to tolerate dual antiplatelet therapy. The objective of this study was to demonstrate the feasibility of magnetic cell capture to rapidly endothelialize intracoronary stents in a large animal model. A novel stent was developed from a magnetizable duplex stainless steel (2205 SS). Polylactic-co-glycolic acid and magnetite (Fe3O4) were used to synthesize biodegradable superparamagnetic iron oxide nanoparticles, and these were used to label autologous blood outgrowth endothelial cells. Magnetic 2205 SS and nonmagnetic 316L SS control stents were implanted in the coronary arteries of pigs (n = 11), followed by intracoronary delivery of magnetically labeled cells to 2205 SS stents. In this study, we show extensive endothelialization of magnetic 2205 SS stents (median 98.4% cell coverage) within 3 days, whereas the control 316L SS stents exhibited significantly less coverage (median 48.9% cell coverage, p < 0.0001). This demonstrates the ability of intracoronary delivery of magnetic nanoparticle labeled autologous endothelial cells to improve endothelialization of magnetized coronary stents within 3 days of implantation.
Get full access to this article
View all access options for this article.
References
1.
GilardM., BarraganP., NoryaniA.A., et al.6- Versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol, 65, 777, 2015.
2.
ColomboA., ChieffoA., FrasheriA., et al.Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol, 64, 2086, 2014.
3.
MauriL., KereiakesD.J., YehR.W., et al.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med, 371, 2155, 2014.
4.
DuckersH.J., SoullieT., den HeijerP., et al.Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). EuroIntervention, 3, 350, 2007.
5.
JantzenA.E., LaneW.O., GageS.M., et al.Use of autologous blood-derived endothelial progenitor cells at point-of-care to protect against implant thrombosis in a large animal model. Biomaterials, 32, 8356, 2011.
6.
KempeH., KatesS.A., and KempeM.Nanomedicine's promising therapy: magnetic drug targeting. Expert Rev Med Devices, 8, 291, 2011.
7.
PanY., DuX., ZhaoF., and XuB.Magnetic nanoparticles for the manipulation of proteins and cells. Chem Soc Rev, 41, 2912, 2012.
8.
ChornyM., FishbeinI., AdamoR.F., ForbesS.P., Folchman-WagnerZ., and AlferievI.S.Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis. Methodist Debakey Cardiovasc J, 8, 23, 2012.
9.
ChornyM., FishbeinI., ForbesS., and AlferievI.Magnetic nanoparticles for targeted vascular delivery. IUBMB Life, 63, 613, 2011.
10.
PislaruS.V., HarbuzariuA., GulatiR., et al.Magnetically targeted endothelial cell localization in stented vessels. J Am Coll Cardiol, 48, 1839, 2006.
11.
PolyakB., FishbeinI., ChornyM., et al.High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A, 105, 698, 2008.
12.
PislaruS.V., HarbuzariuA., AgarwalG., et al.Magnetic forces enable rapid endothelialization of synthetic vascular grafts. Circulation, 114, I314, 2006.
13.
UthamarajS., TefftB.J., KlabusayM., HlinomazO., SandhuG.S., and Dragomir-DaescuD.Design and validation of a novel ferromagnetic bare metal stent capable of capturing and retaining endothelial cells. Ann Biomed Eng, 42, 2416, 2014.
14.
UthamarajS., TefftB.J., HlinomazO., SandhuG.S., and Dragomir-DaescuD.Ferromagnetic bare metal stent for endothelial cell capture and retention. J Vis Exp, 103, e53100, 2015.
15.
TefftB.J., UthamarajS., HarburnJ.J., KlabusayM., Dragomir-DaescuD., and SandhuG.S.Cell labeling and targeting with superparamagnetic iron oxide nanoparticles. J Vis Exp, 105, e53099, 2015.
16.
MooreC.G., CarterR.E., NietertP.J., and StewartP.W.Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci, 4, 332, 2011.
17.
GulatiR., JevremovicD., PetersonT.E., et al.Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res, 93, 1023, 2003.
18.
LeeS.J., JeongJ.R., ShinS.C., et al.Nanoparticles of magnetic ferric oxides encapsulated with poly(d,l latide-co-glycolide) and their applications to magnetic resonance imaging contrast agent. J Magn Magn Mater, 272, 2432, 2004.
19.
LeeS.J., JeongJ.R., ShinS.C., et al.Magnetic enhancement of iron oxide nanoparticles encapsulated with poly(d,l-latide-co-glycolide). Colloid Surface A, 255, 19, 2005.
20.
GeG., WuH., XiongF., et al.The cytotoxicity evaluation of magnetic iron oxide nanoparticles on human aortic endothelial cells. Nanoscale Res Lett, 8, 215, 2013.
21.
YangF.Y., YuM.X., ZhouQ., ChenW.L., GaoP., and HuangZ.Effects of iron oxide nanoparticle labeling on human endothelial cells. Cell Transplant, 21, 1805, 2012.
22.
YangJ.X., TangW.L., and WangX.X.Superparamagnetic iron oxide nanoparticles may affect endothelial progenitor cell migration ability and adhesion capacity. Cytotherapy, 12, 251, 2010.
23.
IngramD.A., MeadL.E., TanakaH., et al.Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood, 104, 2752, 2004.
24.
LinY., WeisdorfD.J., SoloveyA., and HebbelR.P.Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest, 105, 71, 2000.
25.
ChadeA.R., ZhuX., LaviR., et al.Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation, 119, 547, 2009.
26.
GulatiR., JevremovicD., WittT.A., et al.Modulation of the vascular response to injury by autologous blood-derived outgrowth endothelial cells. Am J Physiol Heart Circ Physiol, 287, H512, 2004.
27.
ZohraF.T., MedvedM., LazarevaN., and PolyakB.Functional behavior and gene expression of magnetic nanoparticle-loaded primary endothelial cells for targeting vascular stents. Nanomedicine, 10, 1391, 2015.
28.
DanhierF., AnsorenaE., SilvaJ.M., CocoR., Le BretonA., and PreatV.PLGA-based nanoparticles: an overview of biomedical applications. J Control Release, 161, 505, 2012.
29.
KumariA., YadavS.K., and YadavS.C.Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces, 75, 1, 2010.
30.
LoC.T., Van TasselP.R., and SaltzmanW.M.Poly(lactide-co-glycolide) nanoparticle assembly for highly efficient delivery of potent therapeutic agents from medical devices. Biomaterials, 31, 3631, 2010.
31.
ShiveM.S., and AndersonJ.M.Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 28, 5, 1997.
32.
KwonH.Y., LeeJ.Y., ChoiS.W., JangY.S., and KimJ.H.Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloid Surface A, 182, 123, 2001.
33.
LemoineD., FrancoisC., KedzierewiczF., PreatV., HoffmanM., and MaincentP.Stability study of nanoparticles of poly(epsilon-caprolactone), poly(d,l-lactide) and poly(d,l-lactide-co-glycolide). Biomaterials, 17, 2191, 1996.
34.
SemeteB., BooysenL., LemmerY., et al.In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine, 6, 662, 2010.
35.
CorotC., RobertP., IdeeJ.M., and PortM.Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev, 58, 1471, 2006.
36.
ProvenzanoR., SchillerB., RaoM., CoyneD., BrennerL., and PereiraB.J.Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol, 4, 386, 2009.
37.
SchwenkM.H.Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy, 30, 70, 2010.
38.
LevyM., LucianiN., AlloyeauD., et al.Long term in vivo biotransformation of iron oxide nanoparticles. Biomaterials, 32, 3988, 2011.
39.
LiL., JiangW., LuoK., et al.Superparamagnetic iron oxide nanoparticles as MRI contrast agents for non-invasive stem cell labeling and tracking. Theranostics, 3, 595, 2013.
40.
NkansahM.K., ThakralD., and ShapiroE.M.Magnetic poly(lactide-co-glycolide) and cellulose particles for MRI-based cell tracking. Magn Reson Med, 65, 1776, 2011.
41.
GranotD., NkansahM.K., BennewitzM.F., TangK.S., MarkakisE.A., and ShapiroE.M.Clinically viable magnetic poly(lactide-co-glycolide) particles for MRI-based cell tracking. Magn Reson Med, 71, 1238, 2014.
42.
YuM., HuangS., YuK.J., and ClyneA.M.Dextran and polymer polyethylene glycol (PEG) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture. Int J Mol Sci, 13, 5554, 2012.
43.
AstaninaK., SimonY., CaveliusC., PetryS., KraegelohA., and KiemerA.K.Superparamagnetic iron oxide nanoparticles impair endothelial integrity and inhibit nitric oxide production. Acta Biomater, 10, 4896, 2014.
44.
WuX., TanY., MaoH., and ZhangM.Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int J Nanomedicine, 5, 385, 2010.
45.
HuangZ.Y., PeiN., WangY.Y., et al.Deep magnetic capture of magnetically loaded cells for spatially targeted therapeutics. Biomaterials, 31, 2130, 2010.
46.
YellenB.B., ForbesZ.G., HalversonD.S., et al.Targeted drug delivery to magnetic implants for therapeutic applications. J Magn Magn Mater, 293, 647, 2005.
47.
AdamoR.F., FishbeinI., ZhangK., et al.Magnetically enhanced cell delivery for accelerating recovery of the endothelium in injured arteries. J Controlled Release, 222, 169, 2016.
48.
PolyakB., MedvedM., LazarevaN., et al.Magnetic nanoparticle-mediated targeting of cell therapy reduces in-stent stenosis in injured arteries. ACS Nano, 10, 9559, 2016.
49.
KempeM., KempeH., SnowballI., et al.The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy. Biomaterials, 31, 9499, 2010.
50.
ChornyM., FishbeinI., YellenB.B., et al.Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A, 107, 8346, 2010.
AvilesM.O., ChenH.T., EbnerA.D., RosengartA.J., KaminskiM.D., and RitterJ.A.In vitro study of ferromagnetic stents for implant assisted-magnetic drug targeting. J Magn Magn Mater, 311, 306, 2007.
53.
CarterA.J., LairdJ.R., FarbA., KufsW., WorthamD.C., and VirmaniR.Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol, 24, 1398, 1994.
54.
FarbA., SangiorgiG., CarterA.J., et al.Pathology of acute and chronic coronary stenting in humans. Circulation, 99, 44, 1999.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
